A Phase 2, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-paclitaxel in Participants with previously Untreated, PD-L1 Positive, Locally Advanced Unresectable or Metastatic Triple Negative breast Cancer
Some Exclusions/Inclusions:
Metastatic or locally advanced unresectable, histologically documented triple-negative breast cancer, HER2-low-status, and measurable disease.